Full Access with Signal8 Pro, $49/mo billed annually.
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.
Sector: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Industry: Medical - Instruments & Supplies
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 7.02M shares outstanding
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life.
The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues.
The company was established in 2004 and operates from its headquarters in Herzliya, Israel.
Ehud Geller
CEO & Executive Chairman
Arie Gordashnikov
Chief Accounting Officer
Dror Seliktar
Co-Founder & Chief Scientific Officer
Galit Reske
Chief Medical Officer
Employees
10
Country
IL
Sector
Healthcare
Website
regentis.co.il
Loading congressional disclosures…
based on 7.02M shares outstanding
30d Avg
63.16K
60d Avg
51.49K
90d Avg
76.13K